Interferon gamma (IFN-γ) Production by T- Cells Following Exposure to Various Antigens
Interferon gamma (IFN-γ) is an important immunoregulatory cytokine produced by immune cells primarily by activated natural killer (NK) cells, activated Th1 cells and activated CD8+ cytotoxic cells. IFN-γ can be also produced by macrophages, mast cells, dendritic cells, neutrophils, and peripheral T cells. In addition to its main function in anti-viral immune defense, IFN-γ acts as an anti-proliferative and immunoregulatory factor. It also induces the production of cytokines and upregulates the expression of various membrane proteins including class I and II MHC antigens, Fc receptors, leukocyte adhesion molecules, and B7 antigen. IFN-γ is a potent activator of macrophage effector functions and it can potentiate the secretion of immunoglobulins by B cells. IFN-γ is also involved in the T-helper cell activation pathway.
Allograft recipient T lymphocytes are the key initiators and mediators of the alloimmune response that leads to acute and chronic rejection of an allograft kidney. Measurement of secretion of IFN-γfrom induced (activated) T lymphocytes presents a very good tool to measure the frequency of a population of T cells capable of responding to an antigen by secretion of cytokines. This is the principle of the assay for monitoring T cell alloreactivity in certain types of solid organ transplant rejection.
The enzyme-linked immunosorbent spot assay for interferon gamma (IFN-γ ELISPOT) represents a promising tool for posttransplant monitoring of of T cell alloreactivity and solid organ transplant rejection and in pretransplant immune risk assessment. Currently this assay is primary used in kidney transplantation for T cell monitoring after transplantation, and as a pretransplant measure of immune risk for kidney transplant rejection. In the posttransplant setting, relatively low IFN-γ ELISPOTs may be predictive of long-term graft function. Higher values later after transplantation tend to correlate with clinical and histologic signs of chronic rejection.
The basis of the assay is that a programmed T cell will react to a specific antigen by secretion of a cytokine. However, the antigen can be any number of substances. This assay has been extensively evaluated for its ability to estimate the frequency of antiviral effector cells and assessment of antitumor responses. It can be also be used for the quantification of immune responses to vaccines of various sorts including anti-melanoma vaccines. Also this technique can be used to assess for the presence of latent (not clinically apparent) infectious diseases such as tuberculosis, for which it is much more specific than the PPD skin test.
- Assessment of T cell immunity in solid organ transplant recipients
- Post-transplant monitoring of T cell reactivity
- Pre-transplant immune risk assessment for patients undergoing kidney transplantation
- Assessment of immunity against viral infections such as hepatitis C and HIV
- Assessment of antitumor response
- Detection of latent infectious diseases such as tuberculosis
- IFN-γ ELISPOT Positive Post-kidney transpant indicates heightened T cell alloreactivity and is predictive of poor long-term graft function
- IFN-γ ELISPOT Positive in Pre-kidney transplant organ recipient T-cells correlates with acute rejection after kidney transplantation
Negative (consult with testing laboratory for cutoff values and specific reference range)
Whole blood collected in EDTA (lavender top tube) or other anticoagulant containing tubes.
Stability
- Ambient: 1-3 days
- Refrigeration: 7 days
- Frozen: Not applicable
- Clin Chim Acta. 2012 Sep 8;413(17-18):1359-63. [PMID: 22732764]
- Transl Res. 2012 Sep;160(3):230-6. [PMID: 22683414]
- Am J Transplant. 2005 Aug;5(8):1971-5. [PMID: 15996247]
- Expert Rev Vaccines. 2011 Mar;10(3):299-306. [PMID: 21434798]
- J Immunol Methods 65 (1–2):109–121. [PMID: 6361139].
- The Lancet. 23 June 2001; 357(9273):2017–2021. [PMID: 11438135].
- R&D Systems, Inc. ELISpot, for the quantitative determination of the frequency of cells releasing human IFN-γ. Package insert (Catalog Number EL285). © 2011 R&D Systems, Inc.